Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2

Status

Recruiting 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 2Waldenstrom Macroglobulinemia 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, B-Cell 1Hematologic Neoplasms 1

Interventions

Specimen Handling 123Magnetic Resonance Spectroscopy 99Biopsy 72pembrolizumab 58Carboplatin 55Nivolumab 54Cisplatin 53Cyclophosphamide 51Paclitaxel 41Bevacizumab 36Radiotherapy 33Gemcitabine 33Dexamethasone 30Doxorubicin 25atezolizumab 24Fluorouracil 24olaparib 23Rituximab 23Pemetrexed 23fludarabine 22durvalumab 21Radiation 21Cytarabine 21venetoclax 20Vincristine 20Prednisone 20Oxaliplatin 20Ipilimumab 20Injections 20Lenalidomide 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × ARQ531 × 30 days × Clear all
NCT07194980 2026-06-05

Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Fred Hutchinson Cancer Center

Phase 2 Recruiting
20 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04728893 2026-05-26

MK-1026-003

Merck Sharp & Dohme LLC

Phase 2 Recruiting
490 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, B-Cell, Hematologic Neoplasms

NCT06863402 2026-05-20

Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype

Roswell Park Cancer Institute

Phase 2 Recruiting
32 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡